GlassScriptPhysician profile
Thomas M Hubbard
NPI 1588633267
$8,925.34
in general payments reported to CMS, 2019-2025
45 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $1,151 · 2021: $1,340 · 2022: $1,408 · 2023: $1,672 · 2024: $1,451 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,311.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,933.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $904.82 | 2021-2025 | |
| Amgen INC. | $876.40 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $735.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $597.04 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Esperion Therapeutics, INC. | $507.13 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $458.45 | 2019-2022 | |
| Allergan, INC. | $442.63 | 2019-2021 | |
| Pfizer INC. | $396.75 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.79 | 2019-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $240.31 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $153.44 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $124.27 | 2019-2022 | |
| Abbott Laboratories | $114.12 | 2019-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $110.64 | 2021-2024 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mentor Worldwide LLC | $105.33 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $80.33 | 2021 | |
| Horizon Therapeutics Plc | $64.25 | 2023 | Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $63.28 | 2022 | |
| Exact Sciences Corporation | $59.36 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $59.13 | 2023-2025 | Watchman Access System |
| Sanofi-Aventis U.S. LLC | $57.68 | 2022 | |
| Idorsia Pharmaceuticals US INC | $50.91 | 2023 | Quviviq |
| Dexcom, INC. | $44.94 | 2024-2025 | Dexcom G6 Transmitter |
| Organogenesis INC. | $39.25 | 2023 | Puraply |
| Mannkind Corporation | $38.25 | 2020 | |
| Merck Sharp & Dohme LLC | $37.62 | 2019-2021 | |
| Philips North America LLC | $36.99 | 2024 | (Ck6) Holter |
| Sanofi Pasteur INC. | $35.41 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $31.82 | 2019-2021 | |
| Atricure, INC. | $25.56 | 2022 | |
| Clarus Therapeutics INC. | $25.35 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.93 | 2022 | |
| Organon LLC | $22.88 | 2022 | |
| Astellas Pharma US INC | $21.73 | 2019 | |
| Antares Pharma, INC. | $20.06 | 2025 | Xyosted |
| Lundbeck LLC | $19.75 | 2022 | |
| Collegium Pharmaceutical, INC. | $19.42 | 2025 | Jornay Pm |
| Baxter Healthcare | $18.22 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Watermark Medical, INC. | $18.12 | 2024 | |
| Genentech USA, INC. | $16.00 | 2021 | |
| Seqirus USA INC | $15.57 | 2024 | Fluad, Flucelvax |
| Medtronic, INC. | $13.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.36 | 2024 | Trintellix |
| Augmedics INC. | $12.08 | 2023 | Xvision |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.